OFFICIALS LEGISLATION INTEREST GROUPS PUBLIC STATEMENTS COMMITTEES VETOES

Disinterment of Remains of Fernando V. Cota From Fort Sam Houston National Cemetery, Texas

Floor Speech

Date: Dec. 11, 2025
Location: Washington, DC

BREAK IN TRANSCRIPT

Mr. AUCHINCLOSS. Mr. Speaker, I rise today to outline my concerns with a provision contained within the Fiscal Year 2026 National Defense Authorization Act, which I will vote against. This provision, though well intentioned, is poorly drafted and shows the deficit of proper process.

Referred to as the BIOSECURE Act, Section 851 of the NDAA will only apply to contracts subject to the Federal Acquisition Regulations System--that is the Department of Defense and Department of Veterans Affairs. This means that while Medicare and commercial-plan beneficiaries will be able to access the drugs captured by the BIOSECURE Act, veterans and service members could be alienated from treatments and cures that are available to other Americans. This bifurcation is not only unfair, it renders the disincentive to biotechs ineffective.

In its form, this bill is not fit to function and makes no attempt to support a domestic CDMO or CRO industry. It simply limits care and cures for service members and veterans.

BREAK IN TRANSCRIPT


Source
arrow_upward